Compare HBIO & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBIO | PDSB |
|---|---|---|
| Founded | 1901 | 2005 |
| Country | United States | United States |
| Employees | 339 | 10 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.9M | 29.6M |
| IPO Year | 2000 | 2015 |
| Metric | HBIO | PDSB |
|---|---|---|
| Price | $5.29 | $1.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $18.00 | $9.00 |
| AVG Volume (30 Days) | 36.7K | ★ 952.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,176,000.00 | N/A |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $8.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $0.51 |
| 52 Week High | $7.50 | $1.90 |
| Indicator | HBIO | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 42.60 | 60.57 |
| Support Level | $4.42 | $0.85 |
| Resistance Level | $5.79 | $1.40 |
| Average True Range (ATR) | 0.45 | 0.16 |
| MACD | -0.27 | 0.02 |
| Stochastic Oscillator | 1.33 | 66.39 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.